Cooley LLP announced today that it represented AcelRx Pharmaceuticals, Inc. in its public offering of approximately 4.8 million shares of common stock. AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.

The offering closed on July 23, 2013.

The chair of Cooley’s medical device practice, Mark Weeks, led the offering, and he teamed with partner Chadwick Mills and special counsel Marina Remennik on corporate securities matters. Partners Natasha Leskovsek, Mark Windfeld-Hansen, Scott Talbot, Thomas Blinka, and associates Steven Hwang, David Ambler, John Mills and Andrew Keith also provided support on this transaction.

Cooley represented AcelRx in its initial public offering in February 2011.

View the AcelRx press release here.


Related Posts:

Leave a Reply